Tai­ho antes up an ex­tra $250M for its ven­ture arm as it gets se­ri­ous about 'glob­al on­col­o­gy' deals

Japan’s Tai­ho Phar­ma has been scout­ing the globe for in­no­va­tions to com­ple­ment its on­col­o­gy drug dis­cov­ery pipeline — and it now ap­pears ready to spend on them.

Tai­ho Ven­tures, the Men­lo Park-based cor­po­rate VC arm of the Ot­su­ka sub­sidiary, has re­loaded its in­vest­ment pool with $250 mil­lion on top of the $50 mil­lion ini­tial­ly in­vest­ed in 2016, which has so far yield­ed a port­fo­lio that fea­tures Ar­cus Bio­sciences, PACT Phar­ma, Har­poon Ther­a­peu­tics, Storm Ther­a­peu­tics, ORIC Phar­ma­ceu­ti­cals and Quen­tis Ther­a­peu­tics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER